At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Individualized (Timed) Temozolomide Administration as a Means of Immune Reconstitution in Patients With Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating temozolomide, flow cytometry, and 3 other interventions for Recurrent Melanoma and Stage IV Melanoma. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This clinical trial studies individualized temozolomide (TMZ) in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as TMZ, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving TMZ at different times, which are determined individually for each patient based on the phase (biorhythm) of the immune system response against the tumor may allow for a better drug response and may kill more tumor cells
Study Details
Timeline
Interventions
Given PO
Correlative studies
Correlative studies
Optional correlative studies
Correlative studies